Russia says India to produce 100 million doses of Sputnik vaccine Apart from India, the RDIF says Sputnik V will also be produced in Brazil, China and South Korea. Russian President Vladimir Putin wearing protective gear walks at a hospital for patients infected with the coronavirus disease (COVID-19) on the outskirts of Moscow, Russia March 24, 2020 [Alexey Druzhinin/Kremlin/Sputnik via Reuters] One of the developers of Russia’s Sputnik V coronavirus vaccine announced on Friday that India-based drugmaker Hetero will produce more than 100 million doses of the jab. “Hetero, one of India’s leading generic pharmaceutical companies, have agreed to produce in India over 100 million doses per year of the world’s first registered vaccine against the novel coronavirus infection – Sputnik V,” the Russian Direct Investment Fund (RDIF) said in a statement, adding that production was expected to start in early 2021. Earlier this week, Russia said interim results from the Sputnik V clinical trials showed the vaccine was 95 percent effective, similar to other international vaccine makers that have also published test results showing efficacy rates of 90 percent and higher. Russia this contact form also announced the Sputnik V vaccine will be priced at $10 per dose on international markets, costing less than some other registered COVID-19 vaccines. Russia was the first country to announce the registration of a coronavirus vaccine in August – dubbed Sputnik V after the Soviet-era satellite – but did so ahead of large scale clinical trials. Currently, the third and final phase of trials is under way, with some 40,000 volunteers involved in blind testing of the vaccine that uses two different human adenovirus vectors. According to Friday’s statement, their use “allows for a stronger and longer-term immune response” compared with vaccines that use the same vector in both its doses. Third phase trials are also under way in the ex-Soviet republic of Belarus, the UAE and Venezuela among other countries.

https://www.aljazeera.com/news/2020/11/27/russia-says-india-to-produce-100-million-doses-of-sputnik-vaccine

Engleberg | November 27, 2020 at 10:00 AM Your article was successfully shared with the contacts you provided. Credit: Andrii Yalansky / Shutterstock.com “Order to Show Cause Denied. This application involves financial relief. See Crowe v. De Gioia, 90 N.J. 126 (1982). File a Motion in the ordinary course.” Whether you have been on the winning or losing side of this type of decision, you have seen similar legal “reasoning.” But, did you know that financial matters—or, more properly stated, the consequences that flow from financial matters—may be ripe for consideration under Crowe? Access to the entire ALM network of websites Unlimited access to the ALM suite of newsletters Build custom alerts on any search topic of your choosing A multitude of factors combined during the pandemic to create a perfect breeding ground for an increase in domestic violence. Teva and affiliated companies are fighting an attempt to create multidistrict litigation for more than 55 lawsuits brought over the Paragard IUD, a birth control device.

https://www.law.com/njlawjournal/2020/11/27/seeking-injunctive-financial-relief-in-family-part-eating-and-digesting-crowe/